RECKITT BENCKIS/S (OTCMKTS:RBGLY) – Equities research analysts at Jefferies Financial Group dropped their FY2020 earnings estimates for RECKITT BENCKIS/S in a research report issued on Friday, November 15th. Jefferies Financial Group analyst M. Deboo now anticipates that the company will post earnings per share of $0.83 for the year, down from their previous estimate of $0.86. Jefferies Financial Group also issued estimates for RECKITT BENCKIS/S’s FY2021 earnings at $0.84 EPS and FY2022 earnings at $0.86 EPS.
Other equities analysts have also recently issued reports about the company. Berenberg Bank began coverage on RECKITT BENCKIS/S in a research note on Wednesday, October 16th. They issued a “buy” rating on the stock. ValuEngine cut RECKITT BENCKIS/S from a “buy” rating to a “hold” rating in a research note on Thursday, October 17th. Two research analysts have rated the stock with a sell rating, three have issued a hold rating and two have issued a buy rating to the company. RECKITT BENCKIS/S has an average rating of “Hold” and a consensus target price of $19.00.
About RECKITT BENCKIS/S
Reckitt Benckiser Group plc manufactures, markets, and sells health, hygiene, and home products. The company offers products for the treatment of analgesic and gastro-intestinal problems, sore throat, cough, pain, and flu, as well as wellness products in sexual wellbeing, footcare, vitamins, and supplements under the Durex, Gaviscon, Nurofen, Mucinex, Scholl/Amopé, and Strepsils brand names.
Further Reading: What is the QQQ ETF?
Receive News & Ratings for RECKITT BENCKIS/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RECKITT BENCKIS/S and related companies with MarketBeat.com's FREE daily email newsletter.